The European Union has granted CE mark approval to BiO2 Medical's inferior vena cava (IVC) filter for use in critically ill patients who are at increased risk of pulmonary embolism and temporarily contraindicated for anticoagulation therapy.
Placed at the patient’s bedside, the triple lumen Angel Catheter is a nitinol-based retrievable IVC filter which is permanently attached to a multi-lumen central venous catheter (CVC).
In addition to administration of medications, fluids, or blood products, the CVC is used for blood sampling and monitoring central venous pressure.
BiO2 Medical chairman and chief executive officer Christopher Banas said, "We are pleased to provide physicians with a technology that offers immediate Pulmonary Embolism protection for ICU patients during the critical unprotected window, while simultaneously allowing for lifesaving fluid and medication administration."
The company said it will launch the first IVC filter at the UK Intensive Care Society’s state of the art’ meeting being held in London, England.